BRCA1 and neoplasm: PARP inhibitors impair SSB repair to cause tumor cells to transform into DNA DSBs in the S phase, which leads to cell death due to mitotic catastrophe or apoptosis in tumors with BRCA1 and BRCA2 mutations as well as an HR deficiency (24).